Data topics

Most CPG teams can see that market share moved, but not why—because they rely on slow, manual “share analysis” that stops at charts instead of diagnosis. The blog explains how proper market share decomposition should break a change into concrete drivers (distribution, velocity, price/mix, and competitive moves) at retailer, region, and segment level, instead of confusing simple correlations or national averages with true attribution. It shows how AI automates the hard parts—data integration, baseline modeling, and competitive tracking—so brand managers can ask “Why did share drop at Kroger last month?” and instantly see quantified drivers and recommended actions. With this always-on decomposition, teams move from week-long investigations and stale insights to fast, retailer-specific decisions that actually recover and grow share.

This guide lays out a complete picture of where augmented analytics is headed in 2025. It goes beyond buzzwords to explain how AI agents, conversational interfaces, generative insights, and governed semantic layers combine to deliver more than just “what happened”—they show why things change and what to do next. Expect deep dives into agentic workflows, scalability, governance challenges, and real use cases across industries. Whether you’re redesigning your data stack or evaluating new analytics tools, this is your roadmap to making augmented analytics work in practice.

When pharma brands strike major deals, they don’t just gain access—they inherit complex tradeoffs. From navigating volume vs. margin to managing payer fatigue, these tradeoffs shape strategy long after contracts are signed. This blog breaks down five recurring tensions in market access and shows how AI-powered analytics helps commercial and HEOR teams model scenarios, simulate outcomes, and move from rigid strategy to adaptive execution.

With the FDA’s landmark approval of CAR-T therapies like Abecma and Carvykti as earlier-line treatments, the commercial landscape is shifting rapidly. This blog explores the next phase of CAR-T market access and the analytics brand teams need to navigate it. Learn how to forecast pull-through, identify high-opportunity accounts, and guide sales execution using real-world data, segmentation strategies, and AI-powered insights. From payer dynamics to provider referral patterns, find out what it takes to win in a competitive, high-cost therapeutic space.

Faster drug approvals are coming. Here's how field sales, market access, and brand teams must adapt—and why AI analytics is no longer optional.

Key learnings from Novo Nordisk to help you along your journey to unlocking business value with AI in the commercial pharmaceutical space.

Learn how AI-powered approaches to pharmaceutical and biotech pricing, contracting, rebates, and revenue management are helping commercial and market access teams navigate common challenges.

Market access teams at pharmaceutical & life science organizations are critical to commercial success. Here's how AI-powered approaches can help.

Tellius has announced a partnership with Indegene, a technology-led healthcare solutions provider. The partnership will leverage Indegene’s deep domain knowledge in life sciences and expertise in advanced data and analytics, empowering companies with data at scale and AI-driven analytics that enable faster and better business decisions.